Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients 3 years old or greater at the time of informed consent~2. Patients who are diagnosed as definite diagnosis according to diagnostic criteria for tuberous sclerosis complex (International Tuberous Sclerosis Complex Consensus Conference 2012)~3. Patients with three or more papules of angiofibroma ( \>= 2 mm in diameter with redness in each) on the face at screening tests~4. Patients who are not suitable for therapy with laser or surgery, or who do not want therapy with laser or surgery~5. Patients or his/her guardian who give a written informed consent in understanding and willingness after having received enough explanation of the test drug and the current trial plan~Exclusion Criteria:~1. Patients who are hard to apply the test drug topically with keeping compliance~2. Patients with clinical findings such as erosion, ulcer and eruption on or around the lesion of angiofibroma, which may affect assessment of safety or efficacy~3. Patients who are hard to be taken pictures of their lesions adequately in such cases that they may not follow instruction of stillness~4. Patients with a history of hypersensitivity to alcohol or allergy to sirolimus~5. Patients who have complications such as malignant tumor, infection, serious heart disease, hepatic function disorder, renal function disorder or blood disorders which severity are considered by investigator as grade 2 or more severe with reference to ''Concerning classification criteria for seriousness of adverse drug reactions of medical agents''~6. Patients who have complications such as diseases unsuitable for the trial participation, for examples, uncontrolled diabetes (fasting blood glucose level \>140 mg/dL or postprandial blood glucose level \> 200 mg/dL), dyslipidemia (cholesterol level \> 300 mg/dL or \> 7.75 mmol/L, triglycerides level \> 300 mg/dL or \> 3.42 mmol/L), etc.~7. Patients who have taken drugs with mTOR inhibitory action including sirolimus, everolimus or temsirolimus within 12 months before the initial registration~8. Patients who have applied topical tacrolimus on the lesion of angiofibroma within 3 months before the initial registration~9. Patients who have received therapy with laser or surgery to the lesion of angiofibroma within 6 months before the initial registration~10. Female patients who may be pregnancy or are lactating~11. Patients who cannot agree to take appropriate measures of contraception until completion of post-treatment phase or follow-up period after discontinuation from informed consent~12. Patients who have participated in other clinical trial and have taken a trial drug within 6 months before the initial registration~13. Others, patients who are considered by the investigator as unsuitable for participation in the trial

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPC-12G gel (Type: EXPERIMENTAL): NPC-12G gel is containing 0.2% Sirolimus
- Placebo gel (Type: PLACEBO_COMPARATOR): Placebo gel is matched ingredient with NPC-12G gel

Based on this trial design, predict the completion outcome and termination type (if applicable).